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a b s t r a c t
Any molecular recognition reaction supported by a solid phase drives a speciﬁc change of the
solid–solution interfacial tension. Sessile contact angle (CA) experiments can be readily used to track
this thermodynamic parameter, prompting this well-known technique to be reinvented as an alterna-
tive, easy-access and label-free way to probe and study molecular recognition events. Here we deploy
this technique, renamed for this applicationCONAMORE (CONtactAngleMOlecularREcognition), to study
the interaction of the tumor-derived pro-angiogenic vascular endothelial growth factor-A (VEGF-A) with
the extracellular domain of its receptor VEGFR2. We show that CONAMORE recognizes the high afﬁnity
binding of VEGF-A at nanomolar concentrations to surface-immobilized VEGFR2 regardless of the pres-
ence of a ten-fold excess of a non-speciﬁc interacting protein, and that it further proofs its speciﬁcity and
reliability on competitive binding experiments involving neutralizing anti-VEGF-A antibodies. Finally,
CONAMORE shows the outstanding capability to detect the speciﬁc interaction between VEGFR2 and
low molecular weight ligands, such as Cyclo-VEGI, a VEGFR2 antagonist cyclo-peptide, that weighs about
2kDa.
© 2010 Elsevier B.V. All rights reserved.
1. Introduction
Protein–protein interactions are the underlying mechanism
leading to the activity of every biological system in both phys-
iological and pathological conditions. Since pharmacology and
diagnostics are progressing towards speciﬁc molecular targets
and markers, investigation of protein–protein interactions gained
increasing importance in medicine during the last decades. Thus,
the development of innovative sensing platforms able to push for-
ward the understanding of thermodynamics and kinetics of these
interactions at reasonable costs are still an open and demanding
issue (Cheng et al., 2006; Ferrari, 2005).
Protein–protein interactions and their kinetic and thermody-
namic parameters can be directly investigated in solution phase
or on solid phase assays (Marquette and Blum, 2006; Bergese
et al., 2008). Solution phase assays, such as micro-calorimetric
(Falconer et al., 2010), are affected by limitations related to the
use of large amounts of highly puriﬁed proteins (milliliters of pro-
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tein solutions at M concentrations, at least) and to the different
conformation that protein can assume in solution with respect
to cellular environments (Cooper, 2004). On the contrary, solid
phase assaysperformedon intact cells, cellmembranepreparations
or with immobilization of the receptors in “cell-like” environ-
ments have been used to reveal protein–protein interactions and
to study their kinetics. Among these, Enzyme-Linked ImmunoSor-
bent Assay (ELISA) (Wild, 2005), Surface Plasmon Resonance (SPR)
(Rich and Myszka, 2000), radio- or ﬂuorescence-assays (Souriau
and Hudson, 2003; Phizicky and Fields, 1995) and Fluorescence
Resonance Energy Transfer (FRET) (Wu and Brand, 1994) have
to be cited as the most common techniques. Recently, innova-
tive solid phase biosensors have been exploited for the study of
protein–protein binding, including electrochemical or electrical
immunoassays (Zheng et al., 2005) ormicro-mechanical biosensors
(Waggoner and Craighead, 2007).
In this communication we spotlight the study of a
protein–protein interaction by nanoliter contact angle, named, for
this speciﬁc application, CONAMORE (CONtact Angle MOlecular
REcognition). This new label-free assay is based on the observation
that a ligand–receptor interaction supported by a solid phase
drives a speciﬁc change of the solid–solution interfacial tension
(Bergese et al., 2009; Oliviero et al., 2010), that can be straight-
forwardly detected by sessile drop contact angle measurements
0956-5663/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
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Fig. 1. Schematic of sessile drop CA systems at equilibrium formed by a drop of ligand solution (phase B), a receptor-functionalized surface (phase S), and a surrounding
phase (phase C); the CA is indicated by . Panel (a) represents the unspeciﬁc case, where ligands and receptors do not bind; panel (b) represents the speciﬁc case, where
ligands and receptors bind.
(Fig. 1). In particular, we show that the proof-of-concept we imple-
mented to detect DNA duplex formation (Bergese et al., 2009) can
be proﬁtably extended to investigate the more demanding case
of the interactions between soluble protein ligands with their
surface-immobilized cellular receptors. This application marks
down a new path for the contact angle technique as well, that
so far has been exclusively deployed to study physisorption and
wettability of protein ﬁlms (see for e.g., Sigal et al., 1998; Rios and
Smirnov, 2009).
We investigate the interaction between the tumor-produced
pro-angiogenic vascular endothelial growth factor (VEGF-A) at
nanomolar concentrations and the surface-immobilized extracel-
lular domain of its endothelial cell receptor VEGFR2, featuring
VEGF-A/VEGFR2 binding in the presence of non-interacting pro-
teins, competitive binding experiments and detection of binding of
small peptide ligands to VEGFR2. This ligand–receptor system has
a fundamental impact in biomedicine, since it promotes angiogen-
esis, the process of new blood vessel formation from pre-existing
ones that plays a key role in human cancer proliferation (Folkman,
1995). Experimental evidences point to the VEGF-A/VEGFR2 sys-
tem as an important target for the development of anti-angiogenic
therapies aimed at inhibiting the tumor growth and the metastatic
process (Ferrara et al., 2003). Accordingly, neutralizing anti-VEGF-A
antibodies and VEGFR2 inhibitors have shown promising anti-
neoplastic effects in cancer patients (Hurwitz et al., 2004).
CONAMORE results to be very reliable and sensitive. These
aspects together with the label-free nature of the technique
constitute decisive advantages with respect to ELISA, radio- or
ﬂuorescence-assays and electrical or electrochemical immunoas-
says (Morgan et al., 1996; Lee et al., 2009). On the other hand,
the use of minute quantities of ligand solutions – hundreds of
nanoliters, potentially reducible to hundreds of picoliters (Taylor
et al., 2007) – and the low cost of the instrumentation place
CONAMORE in a favorable position to compete with mature label-
free assays such as SPR (Huang et al., 1998) and Isothermal Titration
Calorimetry (ITC) (Kim and Kiick, 2007). Beyond these practi-
cal advantages, the transduction principle of CONAMORE opens
original perspectives in the understanding of thermodynamics
and kinetics of ligand–receptor interactions, in the investigation
of ligand-induced conformational changes and in the identiﬁca-
tion/screening of low molecular weight (LMW) ligands, such as
peptides and drugs.
2. Experimental details
2.1. Biomolecules and chemicals
Recombinant human extracellular domain of VEGFR2-Fc
(sVEGFR2/Fc) chimeras were from RELIATech GmbH (Braun-
schweig, Germany). Human recombinant vascular endothelial
growth factor-A165 (VEGF-A)was fromR&DSystems (Minneapolis,
MN) and bovine serum albumin (BSA) from Sigma–Aldrich, Ger-
many.
VEGF-A was dissolved in phosphate buffered saline (PBS,
Sigma–Aldrich, Germany), pre-equilibrated with cyclohexane
(Sigma–Aldrich,Germany). Solutions ofVEGF-Awere alsoprepared
with the addition of 1M BSA.
Anti-human VEGF-A monoclonal antibody (speciﬁc antibody)
and anti-human IL-8 monoclonal antibody (irrelevant antibody)
(R&D Systems, Minneapolis, MN, USA) were dissolved at a ﬁnal
concentration of 0.01gl−1 in a PBS solution containing 100nM
VEGF-A and 1M BSA.
Cyclo-VEGI (CBO-P11, MW=1998.3Da, Calbiochem, CA, USA)
and VEGF15 (D’Andrea et al., 2005, MW=1948Da) were dissolved
in PBS (with the addition of 1M BSA) in order to obtain a ﬁnal
concentration of 1M.
2.2. Surface functionalization
Surface Plasmon Resonance (SPR) chips with the CM3 func-
tionalization (BIAcore Inc., Piscataway, NJ, USA) were employed as
substrates for the contact angle measurements.
To this purpose, the CM3 chips were detached from the plas-
tic holder, rinsed with HBS-EP buffer (10mM HEPES, pH 7.4,
150mM NaCl, 3mM EDTA, 0.005% surfactant P20, BIAcore Inc.,
Piscataway, NJ, USA) and immersed for 3h in 0.2M N-ethyl-N-
(3-dimethylaminopropyl)-carbodiimidehydrochlorideplus 0.05M
N-hydroxysuccinimide. The surfaces were then washed with HBS-
EP and incubated with 30l of sVEGFR2/Fc (1.87M in 10mM
sodium acetate, pH 3.0) for 2h at 25 ◦C and 14h at 4 ◦C. After
sVEGFR2/Fc immobilization, matrix neutralization was performed
with 1.0M ethanolamine (pH 8.5).
After an accurate HBS-EP wash, the functionalized chips were
brieﬂy immersed in 10mM NaOH, washed with HBS-EP and stored
in PBS at 4 ◦C.
2.3. Protein and peptides binding measurements with
CONAMORE and data analysis
Sessile drop experiments (Adamson and Gast, 2000) for
the determination of the contact angles were carried out at
room temperature with a CAM 200 tensiometer (KSV Instru-
ments, Finland) equipped with a Navitar camera and employing
cyclohexane as surrounding phase. The employed cyclohexane
and the PBS solution were pre-equilibrated in order to avoid
solute exchange between the two phases during the experi-
ments.
Sessile drop measurements on the functionalized chips were
performed depositing drops of the protein and the peptide solu-
tionswith volumes ranging from150 to 250 nanoliters. The contact
angle evolution was monitored for 12min, acquiring an image
every second for the ﬁrst 3min and every 30 s for the remain-
ing 9min. The images were analyzed using the KSV CAM Optical
Contact Angle and Pendent Drop Surface Tension Software 4.04,
ﬁtting the drop proﬁle with the circular or the Young–Laplace
algorithms. Since the droplet spreading kinetics indicated that the
overall (mechanical and chemical) equilibrium with the substrates
was reached about 9min after the drop deposition (see also Fig. 2
and Section 4), the contact angle value of each drop was taken
as the mean value of the last 8 acquired images (from 8.5min to
Author's personal copy
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Fig. 2. (a) Spreading kinetics of droplets of the PBS solution of VEGF-A 100nM (red circles) and of the raw PBS solution (green circles). The variation of the contact angle in
the ﬁrst 9min is due to the attainment of the mechanical and chemical equilibrium between the drop, the solid surface and the surrounding phase (cyclohexane). The red and
green dotted lines identify the contact angle equilibrium values. Not all the tracked contact angles are reported for clarity reasons. (b) Differential solid–solution interfacial
tension, SB , for a PBS solution of VEGF-A 100nM with respect to reference (raw) PBS solution (VEGF-A) compared with the SB for the same solutions after adding BSA
1.0M (VEGF-A with BSA). The area of the graph included between the two dotted lines identiﬁes the error associated to the absolute solid–solution interfacial tension of
the reference PBS solutions, i.e., the background noise of the signal. (c) SB for a PBS solution containing 100nM VEGF-A, 0.01gl−1 of a speciﬁc anti-VEGF-A antibody
and 1.0M BSA with respect to the same solution without VEGF-A (VEGF-A+Ab) compared with the SB for the same solutions but containing an irrelevant antibody in
place of the speciﬁc one (VEGF-A+ Irr-Ab). (d) SB for a PBS solution of VEGF-A 100nM and BSA 1.0M with respect to reference PBS solution of BSA 1.0M, before and
after the treatment of the immobilized receptor VEGFR2 with 6M urea. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of the article.).
12min after the drop deposition). Triplicates of the samedropwere
deposited in line.
After the deposition of the triplicates of each drop, the chips
were reactivated by a brief immersion in 10mM NaOH (to remove
the bound proteins) and subsequent accurate washings with PBS
and Milli-Q water.
The measurements of the interfacial tension between cyclohex-
ane and the protein and peptide solutionswere performed through
the pendant drop method (Adamson and Gast, 2000).
The values of the contact angles and solution–surrounding
phase interfacial tensions were taken as the mean of the three
independent replicates and the errors evaluated as the standard
deviations of the mean.
Contact anglemeasurementswere alsoperformedon substrates
after a treatment in urea in order to unfold the immobilized recep-
tors. The functionalized chips were immersed in a 6M solution of
urea for 30min and then accurately rinsed in HBS-EP buffer.
2.4. ELISA
A 96-well plate was coated for 16h at room temperature with
250ng/ml of sVEGFR2/Fc in PBS at 100l/well. When indicated,
the plate was incubated in cyclohexane for 5min and then washed
with PBS before a 3-h blocking step with 1% BSA. Then, VEGF-A
(20ng/ml dissolved in PBS or in PBS pre-equilibrated with cyclo-
hexane) was added and incubated for 1h at 37 ◦C followed by 1h
incubation at room temperature (Ponticelli et al., 2008). An anti-
humanVEGFmonoclonal antibody (R&DSystem,Minneapolis,MN)
diluted in PBS at 300ng/ml was added to the wells and incubated
for 1h at 37 ◦C followed by 1h incubation at room temperature.
Finally, wells were incubated for 1h at room temperature with a
secondary donkey anti-mouse horseradish peroxidase-conjugated
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
3. Theory and calculation
The equilibrium of a ligand–receptor binding reaction conﬁned
at the interface between a solid functionalized with the recep-
tors and a solution supplying the ligands (Bergese et al., 2007) is
described by the surface van’t Hoff isotherm
rG
0 = − 
[LR]
− RT ln K (1)
where rG0 is the standard molar Gibbs free energy of the reac-
tion in (free) solution,  is the variation of the solid–solution
interfacial tension upon binding, [ LR] is the equilibrium surface
density of the ligand–receptor complexes, K is the surface equi-
librium constant (or binding afﬁnity),1 and R and T are the ideal gas
constant and the absolute temperature, respectively. Eq. (1) quan-
tiﬁes howapart of theGibbs free energy of the reaction is employed
to accommodate binding on the surface, driving the change of the
solid–solution interfacial tension  .
 can be directly evaluated by sessile drop contact angle
experiments. When a droplet is placed onto a solid surface it
1 For further details on the difference between K and the equilibrium constant
in free solution, please refer to Oliviero et al. (2010).
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Table 1
Optical density values for the ELISA experiments. The table shows the absorbance
values registered on immobilizedVEGFR2when incubatedwith a PBS buffered solu-
tion, a PBS buffered solution of VEGF-A 100nM, or a solution of VEGF-A 100nM in
PBS pre-equilibrated with cyclohexane (VEGF-A*) before and after the exposure of
the immobilized receptors to cyclohexane.
Before VEGFR2 exposure
to cyclohexane
After VEGFR2 exposure
to cyclohexane
Vehicle 0.424 0.432
VEGF-A 0.918 0.869
VEGF-A* 0.868 0.875
reaches the equilibrium with the surface and the surroundings at
the contact line at which drop, surface and surroundings meet,
identifying a deﬁnite contact angle  (Young, 1805 and Fig. 1). 
is linked to the interfacial tensions by the Young–Dupré equation
(Adamson and Gast, 2000). CONAMORE roots on this physico-
chemical phenomenon and can be illustratedwith the help of Fig. 1.
Here the surface, S, is functionalizedwitha receptor and thedroplet,
B, is a solution of unspeciﬁc or speciﬁc ligands for the immobilized
receptor (panel (a) or (b), respectively); C is the surrounding phase.
The speciﬁc binding reaction featured by system (b) gives a speciﬁc
contribution to the solid–solution interfacial tension, SB, that is
missed in the interfacial tension of the unspeciﬁc system (a), 0SB,
taken as reference. Thus, as suggested by Eq. (1), speciﬁc binding is
associated to a change (differential) of the solid–solution interfacial
tensions SB = SB − 0SB. In other words, SB can be regarded as
the transduction signal of the speciﬁc binding event. An analogous
concept holds if pure buffer is considered instead of an unspeciﬁc
ligand solution.
As mentioned above, interfacial tensions are related to contact
angles by the Young–Dupré equation, and it can be shown that
for the system under consideration the following equation holds
(Bergese et al., 2009):
SB = SB − 0SB = 0BC cos 0 − BC cos  (2)
where 0 and  are the contact angles of the unspeciﬁc and of the
speciﬁc systems, respectively, and, analogously, 0BC and BC are the
solution–surrounding phase interfacial tensions of the unspeciﬁc
and of the speciﬁc systems, respectively. Eq. (2) allows to directly
determine the transduction signal SB by measuring 0 and  by
sessile drop contact angle experiments, provided that 0BC and BC
were previously determined (for example by pendant drop exper-
iments, see Section 2). Eq. (2) also indicates that in the particular
case inwhich0BC
∼= BC the contact anglesdifference is biunivocally
related to SB, and thus directly probes the speciﬁc binding.
4. Results
4.1. Receptor surface functionality
CONAMORE experiments were performed with cyclohexane as
surrounding phase in order to avoid evaporation of the nanoliter
drops and to enhance the solution contact angles with the sur-
face. Measurement of water solution contact angle under organic
solvents is a reliable method to evaluate the energetics of protein
binding to different surfaces (Sigal et al., 1998). Moreover, from a
theoretical perspective, proteins in non-polar organic solvents pre-
serve their functionality as, in principle, they do not unfold because
of the increased stability of their non-polar groups in such envi-
ronments (Pace et al., 2004). However, to be on the safe side, we
designed and performed ELISA tests to experimentally check the
hypothesis that cyclohexane does not affect the binding capacity
of VEGFR2 and of its ligand VEGF-A.
The results, reported in Table 1, fully conﬁrmed this hypothesis.
Inparticular, theVEGF-A/VEGFR2complex is formedafter theexpo-
sure of the immobilized VEGFR2 to cyclohexane, alsowhenVEGF-A
is dissolved in a PBS solution pre-equilibrated with cyclohexane.
4.2. Ligand–receptor binding experiments
The ﬁrst experiment was the detection of VEGF-A/VEGFR2
speciﬁc binding. To this purpose we measured the differential
solid–liquid interfacial tension, SB, between a PBS solution of
VEGF-A and the raw PBS solution (taken as reference). The con-
centration of VEGF-A was ﬁxed at 100nM in order to have a large
excess of ligand in the deposited drop when compared to the Kd
value for the VEGF-A/VEGFR2 interaction, approximately equal to
30nM (Huang et al., 1998).
Fig. 2 (panel a) shows the evolution with time of the contact
angles of the VEGF-A and PBS (reference) drops. The spreading
kinetics show that the mechanical and chemical equilibrium of
the drops with the surface and the surrounding phase (cyclohex-
ane) is reached about 9min after deposition. By substituting into
Eq. (2) the equilibrium values of the contact angles, 0 =67.5±0.3◦
and  =73.5±1.3◦, and of the solution–cyclohexane interfacial ten-
sions, 0BC = 35.2 ± 0.7mN m−1 and BC =35.2±0.7mNm−1, we
obtainSB =3.5±0.9mNm−1. This value is a signiﬁcant transduc-
tion signal, giving the ﬁrst, solid proof of the possibility to probe the
interaction between VEGF-A and VEGFR2 by CONAMORE.
Next we assessed the capability of CONAMORE to probe the
VEGF-A/VEGFR2 interaction also in the presence of a large molar
excess of proteins that might interfere with the detection of the
complex formation. To this purpose, we chose BSA (Bovine Serum
Albumin) as a demonstrativenon-speciﬁc interactor, since this pro-
tein is used as a carrier in most of the routine techniques aimed
at ligand–receptor binding studies. On this basis, we measured
SB of a PBS solution of VEGF-A 100nM and BSA 1.0M with
respect to a reference PBS solution of BSA 1.0M; we obtained
SB =3.6±0.2mNm−1. As shown in Fig. 2 (panel b) this value
is consistent with the SB measured for the BSA free solutions,
demonstrating that (i) the high concentration of BSA (ten-folds the
concentration of VEGF-A) does not affect the interaction between
VEGF-A and VEGFR2 and that (ii) CONAMORE is extremely reliable
and speciﬁc. In view of these observations and of the lower exper-
imental uncertainty, all the next experiments were performed by
adding to the buffer solution 1.0M BSA as a carrier; this solution
will be hereafter referred as PBS/BSA solution.
The speciﬁcity and reliability of CONAMORE was further tested
through a competition experiment in which a speciﬁc neutralizing
anti-VEGF-A antibody prevents the interaction between VEGF-A
and VEGFR2. As shown in Fig. 2 (panel c) SB for a PBS/BSA
solution containing 100nM of VEGF-A plus 0.01gl−1 of anti-
VEGF-A antibody (Ab) with respect to the reference PBS/BSA
solution is equal to 0.3±0.5mNm−1. This means that CONAMORE,
as expected, indicates that the antibody interacts with VEGF-A and
prevent it from binding VEGFR2. Instead, when the speciﬁc anti-
VEGF-A antibody is replaced by an irrelevant antibody (Irr-Ab) that
does not interfere with the VEGF-A/VEGFR2 binding, SB comes
back to 2.1±0.3mNm−1, which is a value comparable with the
previously measured SB of the VEGF-A/VEGFR2 binding.
Receptor interaction strongly depends on a proper conforma-
tional structure of the receptor that allows the recognition of the
ligand by speciﬁc binding site(s) on the receptor protein surface.
As a proof of the reliability of the CONAMORE signal due to the
interaction between VEGF-A and VEGFR2, we measured SB of a
PBS/BSA solution of VEGF-A 100nM with respect to the reference
PBS/BSA solution onto immobilized VEGFR2 before and after expo-
sure of immobilized VEGFR2 to urea 6M, that completely unfolds
Author's personal copy
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Fig. 3. (a) Differential solid–solution interfacial tension, SB , for a PBS solution of
Cyclo-VEGI 1M with respect to a PBS solution of VEGF15 1M (both the solutions
also contain BSA 1.0M). The area of the graph included between the two dotted
lines identiﬁes the error associated to the absolute solid–solution interfacial tension
of the (reference) VEGF15 solution, i.e., the background noise of the signal.
the immobilized protein (Scholtz et al., 1995). The results, reported
in Fig. 2 (panel d) show that, with the folded VEGFR2, VEGF-A
binding drives a SB equal to 3.0±0.4mNm−1, that is signiﬁ-
cantly different from the one measured with the unfolded VEGFR2,
SB =1.0±0.5mNm−1. This indicates a dramatic suppression of
the speciﬁc interaction between VEGF-A and VEGFR2 following
the disruption of the conformational structure of the receptor. On
the other hand, the binding SB from this experiment is fairly
consistent with the ones obtained in the previous experiments,
bringing an additional proof of the repeatability of CONAMORE
measurements.
CONAMOREwasﬁnally tested for its ability to detect the speciﬁc
interaction of VEGFR2 with low molecular weight (LMW) ligands.
To this purpose we used, as a model ligand, the peptide Cyclo-
VEGI, a well-known VEGFR2 antagonist (Zilberberg et al., 2003)
that weights 1998Da. In order to eliminate the possible contribu-
tion of non-speciﬁc adsorption that may occur when employing
LMW molecules on biopolymer functionalized surfaces (Serizawa
et al., 2007), the LMW peptide VEGF15 was used as the negative
control (D’Andreaet al., 2005).SB for aPBS/BSAsolutionofCyclo-
VEGI 1M with respect to a reference PBS/BSA solution of VEGF15
1M resulted 2.7±1.1mNm−1(Fig. 3), conﬁrming the auspicated
performances of CONAMORE with LMW species.
5. Conclusions
The inedited and successful application of CONAMORE to the
recognition of interactions between cell membrane receptors and
angiogenic growth factors was described. In particular the inter-
action between the immobilized VEGFR2 receptor and nanomolar
concentrations of its speciﬁc ligand VEGF-A was detectable with
a consistent transduction signal in the presence of a ten-fold
molar excess of an unrelated protein (1.0M BSA) or of irrelevant
immunoglobulins and was distinguished from the non-speciﬁc
interactions occurring after denaturation of the receptors. The
extraordinary speciﬁcity, reliability and repeatability of the tech-
nique were conﬁrmed by a competition experiment, where
CONAMORE revealed the VEGF-A/VEGFR interaction suppression
by a neutralizing anti-VEGF-A antibody. Finally, the detection of
the interaction between Cyclo-VEGI, a 2 kDa cyclo-peptide, and
VEGFR2 demonstrates the technique capability to evaluate the
binding of LMW molecules to surface-immobilized proteins.
These experiments spotlight the role that CONAMORE can play
in the studyof protein–protein interactions, being a label-free tech-
nique with an easier access and a lower cost in comparison with
established methods such as SPR or Quartz Crystal Microbalances
(QCM). Furthermore, the recent development of automated pico-
liter instruments candidates CONAMORE as a decisive player in
applications where small volumes of analyte and/or multiplexed
operation are mandatory. Finally, the direct transduction of the
energy of the interactions opens new perspectives, not only in the
widening of the understanding of surface conﬁned ligand–receptor
interactions, but also in the study of interactions that induce con-
formational changes of the proteins and in the identiﬁcation of low
molecular weight receptor agonists and antagonists with potential
therapeutic implications.
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